Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439603 · ClinicalTrials.gov registry record · Phase 2
ANC-501 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 8
- Study locations
NCT05439603: Completed Phase 2 study of Major Depressive Disorder, sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro.
NCT05439603 is a Phase 2 study of Major Depressive Disorder that has completed, run by Ancora Bio, Inc. d/b/a EmbarkNeuro. The registered enrollment target is 15 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439603, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 8
- Study locations
Study Summary
A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
Primary Outcome
The MADRS was utilized as the primary efficacy assessment of the participant's level of depression. The MADRS consists of 10 items, all rated on a scale 0 to 6 with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. Total MADRS score range is 0 to 60. A higher score indicates more severe depression.
Conditions Studied
Interventions
- DRUG ANC-501
Study Locations (8)
Florida
- Florida Behavioral Medicine - Largo
- Innovative Clinical Research, Inc. - Lauderhill
- Combined Research Orlando - Orlando
New York
- Clinilabs Drug development Corporation - New York
- Richmond Behavioral Associates - Staten Island
California
- ATP Clinical Research - Orange
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Oklahoma
- Conrad Clinical Research - Edmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 2 |
What the finished NCT05439603 record still lists
NCT05439603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which ANC-501 is the first listed.
NCT05439603 lists 8 locations in 5 states (Florida, New York, California).
Frequently Asked Questions
What is clinical trial NCT05439603 about?
NCT05439603 is a clinical study titled "ANC-501 in the Treatment of Adults With Major Depressive Disorder". A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
What is the current status of trial NCT05439603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-09-19. Estimated completion is 2023-10-18.
What conditions does trial NCT05439603 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05439603?
The interventions under investigation include: ANC-501 (DRUG).
Who is sponsoring clinical trial NCT05439603?
This trial is sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05439603 being conducted?
This trial has 8 study locations across California, Florida, New Jersey, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05439603's enrollment target sits among peer trials
15 261st of 282 higher than 20 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI